Incyte Corp. (NASDAQ:INCY)’s share price traded up 2.1% during trading on Friday . The company traded as high as $84.69 and last traded at $83.84, with a volume of 540,691 shares traded. The stock had previously closed at $82.14.

A number of equities analysts have commented on the company. Royal Bank Of Canada assumed coverage on Incyte Corp. in a research note on Tuesday, July 12th. They issued an “outperform” rating and a $105.00 price target on the stock. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Incyte Corp. in a research note on Wednesday, June 29th. JMP Securities reissued an “outperform” rating and set a $100.00 target price on shares of Incyte Corp. in a research note on Wednesday, June 15th. BMO Capital Markets reissued a “buy” rating and set a $97.00 target price (up from $91.00) on shares of Incyte Corp. in a research note on Tuesday, June 7th. Finally, Brean Capital reissued a “buy” rating on shares of Incyte Corp. in a research note on Monday, June 6th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $106.87.

The company has a 50 day moving average of $81.34 and a 200-day moving average of $77.30. The company has a market cap of $15.73 billion and a price-to-earnings ratio of 338.02.

Incyte Corp. (NASDAQ:INCY) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.29 by $0.17. The company earned $263 million during the quarter, compared to analysts’ expectations of $266.38 million. The business’s revenue was up 65.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.11) earnings per share. On average, analysts anticipate that Incyte Corp. will post $0.05 EPS for the current fiscal year.

Several large investors have modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Incyte Corp. by 5.5% in the fourth quarter. Vanguard Group Inc. now owns 11,685,539 shares of the biopharmaceutical company’s stock worth $1,267,298,000 after buying an additional 606,470 shares in the last quarter. Mizuho Trust & Banking Co. Ltd. raised its stake in shares of Incyte Corp. by 2.6% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 238,454 shares of the biopharmaceutical company’s stock worth $26,018,000 after buying an additional 6,091 shares in the last quarter. Eaton Vance Management raised its stake in shares of Incyte Corp. by 28.8% in the fourth quarter. Eaton Vance Management now owns 155,012 shares of the biopharmaceutical company’s stock worth $16,811,000 after buying an additional 34,685 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Incyte Corp. by 47.1% in the fourth quarter. Bank of Montreal Can now owns 60,210 shares of the biopharmaceutical company’s stock worth $6,530,000 after buying an additional 19,285 shares in the last quarter. Finally, Gulf International Bank UK Ltd raised its stake in shares of Incyte Corp. by 8.7% in the fourth quarter. Gulf International Bank UK Ltd now owns 47,645 shares of the biopharmaceutical company’s stock worth $5,167,000 after buying an additional 3,800 shares in the last quarter.

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.